US Homeland Security Sees Rapid Growth In Device Cybersecurity Vulnerability Reports

A center inside the US Department of Homeland Security has seen a massive spike in the number of potential medical device cybersecurity vulnerabilities that it has responded to in the past year. The government says it reflects better collaboration and disclosure policies in industry.

'Vulnerability' word in the middle of the computer screen surrounded by numbers zero and one. Image is taken in a small angle. Image has a vintage effect applied.

While US FDA issues alerts for the most severe medical device cybersecurity vulnerabilities, the US Department of Homeland Security (DHS) has seen a spike in potential threats, which it has responded to by issuing advisories.

The growth could have multiple causes, but one likely factors if positive, according to government officials: the industry and security...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cybersecurity

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Scores Of Companies On Board With Medicare Data Interoperability And Digital Health Initiative

 

The Centers for Medicare and Medicaid Services has launched a new program the agency says will allow patients easier access to their health data. More than 60 companies have already signed on.

FDA Publishes Final Cybersecurity Guidance To Replace Final Cybersecurity Guidance

 

The US FDA has issued an updated final guidance document on cybersecurity considerations for medical device manufacturers that replaces a previous final guidance the agency issued in 2023.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?

More from Digital Technologies